Daronrix (pandemic influenza vaccine (whole virion, inactivated, adjuvanted))
Exceptional circumstances
- Region
- 🇪🇺 EU
- Active substance
- pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
- Company
- GlaxoSmithKline Biologicals S.A.
- Status
- Lapsed
- Therapeutic area
- Influenza, Human; Immunization; Disease Outbreaks
- EU approval
- Wed 21 Mar 2007
- Designations
- Exceptional circumstances
- Application
- EMEA/H/C/000706
- ATC
- J07BB01
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance.
Regulatory milestones
No milestones recorded in the last year.
Follow Daronrix
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.